Indefinite Delivery Contract SPE2DX15D9787

The federal contract IDV award SPE2DX15D9787 is a single-award Indefinite Delivery Contract (IDC) valued at up to $4,999,999.00, awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract's ultimate completion date is December 31, 2025, and it enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide. The contract covers various product categories such as injections, tablets, creams, auto-injectors, and specialty medications, positioning DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain and providing direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites.

This IDC is part of the DLA's SPE2DX program and is not associated with any set-aside designations, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains. The contract's broad scope and the company's proven track record of delivering a diverse array of pharmaceutical products to the DLA suggest that this IDC plays a significant role in supporting the ongoing medical supply needs of the U.S. military and its healthcare facilities.